{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:55:29Z","timestamp":1790582129944,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02875-2","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:01:37Z","timestamp":1790550097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transketolase-like 1 potentiates PD-1 blockade in hepatocellular carcinoma by glycolysis to prime dendritic cell lactylation"],"prefix":"10.1038","volume":"11","author":[{"given":"Hengsong","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipeng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanshu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juyue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuozheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5849-0098","authenticated-orcid":false,"given":"Xuehao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8516-819X","authenticated-orcid":false,"given":"Weiwei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"2875_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"2875_CR2","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163\u20131173 (2018).","journal-title":"Lancet"},{"key":"2875_CR3","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2875_CR4","doi-asserted-by":"publisher","first-page":"e004656","DOI":"10.1136\/jitc-2022-004656","volume":"10","author":"Y Xia","year":"2022","unstructured":"Xia, Y. et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J. Immunother Cancer 10, e004656 (2022).","journal-title":"J. Immunother Cancer"},{"key":"2875_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41392-024-01885-2","volume":"9","author":"X Shi","year":"2024","unstructured":"Shi, X. et al. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives. Signal Transduct. Target Ther. 9, 192 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2875_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P. et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"2875_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","volume":"21","author":"TK Kim","year":"2022","unstructured":"Kim, T. K. et al. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat. Rev. Drug Discov. 21, 529\u2013540 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2875_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck, M. et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J. Clin. Oncol. 37, 537\u2013546 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2875_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4132\/jptm.2022.04.25","volume":"56","author":"K Muller","year":"2022","unstructured":"Muller, K. et al. What\u2019s new in breast pathology 2022: WHO 5th edition and biomarker updates. J. Pathol. Transl. Med. 56, 170\u2013171 (2022).","journal-title":"J. Pathol. Transl. Med."},{"key":"2875_CR10","doi-asserted-by":"publisher","first-page":"100380","DOI":"10.1016\/j.esmoop.2021.100380","volume":"7","author":"AG Leone","year":"2022","unstructured":"Leone, A. G. et al. Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score. ESMO Open 7, 100380 (2022).","journal-title":"ESMO Open"},{"key":"2875_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl6422","volume":"377","author":"A Pinson","year":"2022","unstructured":"Pinson, A. et al. Human TKTL1 implies greater neurogenesis in frontal neocortex of modern humans than Neanderthals. Science 377, eabl6422 (2022).","journal-title":"Science"},{"key":"2875_CR12","doi-asserted-by":"publisher","first-page":"113607","DOI":"10.1016\/j.biopha.2022.113607","volume":"154","author":"S Hao","year":"2022","unstructured":"Hao, S. et al. The role of transketolase in human cancer progression and therapy. Biomed. Pharmacother. 154, 113607 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"2875_CR13","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.cmet.2022.08.002","volume":"34","author":"D Guo","year":"2022","unstructured":"Guo, D. et al. Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of I\u03baB\u03b1. Cell Metab. 34, 1312\u20131324.e1316 (2022).","journal-title":"Cell Metab."},{"key":"2875_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41392-024-02082-x","volume":"10","author":"J Chen","year":"2025","unstructured":"Chen, J. et al. Lactate and lactylation in cancer. Signal Transduct. Target Ther. 10, 38 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"2875_CR15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41392-023-01450-3","volume":"8","author":"X Ma","year":"2023","unstructured":"Ma, X. et al. TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance. Signal Transduct. Target Ther. 8, 246 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2875_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.chembiol.2019.11.005","volume":"27","author":"DO Gaffney","year":"2020","unstructured":"Gaffney, D. O. et al. Non-enzymatic lysine lactylation of glycolytic enzymes. Cell Chem. Biol. 27, 206\u2013213.e206 (2020).","journal-title":"Cell Chem. Biol."},{"key":"2875_CR17","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman, I. et al. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity 56, 2188\u20132205 (2023).","journal-title":"Immunity"},{"key":"2875_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345\u2013362 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2875_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","volume":"19","author":"H Yamaguchi","year":"2022","unstructured":"Yamaguchi, H. et al. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat. Rev. Clin. Oncol. 19, 287\u2013305 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2875_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35469-x","volume":"13","author":"Q Li","year":"2022","unstructured":"Li, Q. et al. PRDM1\/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells. Nat. Commun. 13, 7677 (2022).","journal-title":"Nat. Commun."},{"key":"2875_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02383-z","volume":"21","author":"Y Zhu","year":"2021","unstructured":"Zhu, Y. et al. TKTL1 participated in malignant progression of cervical cancer cells via regulating AKT signal mediated PFKFB3 and thus regulating glycolysis. Cancer Cell Int. 21, 678 (2021).","journal-title":"Cancer Cell Int."},{"key":"2875_CR22","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1158\/1078-0432.CCR-09-2604","volume":"16","author":"W Sun","year":"2010","unstructured":"Sun, W. et al. TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin. Cancer Res. 16, 857\u2013866 (2010).","journal-title":"Clin. Cancer Res."},{"key":"2875_CR23","doi-asserted-by":"publisher","first-page":"e75064","DOI":"10.7554\/eLife.75064","volume":"11","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Mechanisms governing target search and binding dynamics of hypoxia-inducible factors. Elife 11, e75064 (2022).","journal-title":"Elife"},{"key":"2875_CR24","doi-asserted-by":"publisher","first-page":"9401","DOI":"10.3390\/ijms21249401","volume":"21","author":"A Bouthelier","year":"2020","unstructured":"Bouthelier, A. et al. Differential contribution of N- and C-terminal regions of HIF1\u03b1 and HIF2\u03b1 to their target gene selectivity. Int. J. Mol. Sci. 21, 9401 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2875_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41392-023-01605-2","volume":"8","author":"ZW Huang","year":"2023","unstructured":"Huang, Z. W. et al. STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia. Signal Transduct. Target Ther. 8, 391 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2875_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25962-0","volume":"12","author":"D Hammerl","year":"2021","unstructured":"Hammerl, D. et al. Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nat. Commun. 12, 5668 (2021).","journal-title":"Nat. Commun."},{"key":"2875_CR27","doi-asserted-by":"publisher","first-page":"eaav7431","DOI":"10.1126\/scitranslmed.aav7431","volume":"12","author":"M Mayoux","year":"2020","unstructured":"Mayoux, M. et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci. Transl. Med. 12, eaav7431 (2020).","journal-title":"Sci. Transl. Med."},{"key":"2875_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201904639","volume":"31","author":"F Gao","year":"2019","unstructured":"Gao, F. et al. Intra\/extracellular lactic acid exhaustion for synergistic metabolic therapy and immunotherapy of tumors. Adv. Mater. 31, e1904639 (2019).","journal-title":"Adv. Mater."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02875-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02875-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02875-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:02:39Z","timestamp":1790578959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02875-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2875"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02875-2","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"418"}}